We hypothesized that HDAC3 inhibition combined with low-dose cranial radiotherapy has the potential to synergistically reduce microglial activation, induce neurotrophic gene expression, preserve memory, and ameliorate common AD protein pathologies. The gene discussed is HDAC3; the disease is Alzheimer disease.